Azitra, Inc. Announces Reverse Stock Split

Company Overview - Azitra, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [7] - The company's lead program, ATR-12, targets Netherton syndrome, a rare chronic skin disease with no approved treatment options [7] - Azitra's ATR-04 program addresses EGFR inhibitor-associated skin toxicity and has received Fast Track designation from the FDA [7] Reverse Stock Split Announcement - Azitra announced a reverse stock split at a ratio of 1 post-split share for every 6.66 pre-split shares, effective August 21, 2025 [1][2] - The reverse stock split will reduce the number of issued shares from approximately 23,476,354 to about 3,524,978 shares [5] - Stockholders will not need to exchange existing stock certificates, as shares held in brokerage accounts will be automatically adjusted [3][4] Stockholder Impact - The reverse stock split will affect all stockholders uniformly, maintaining their percentage interest in the company's equity, except for fractional shares [4] - Stockholders entitled to fractional shares will receive cash in lieu of those shares, calculated based on the average closing sales prices for the five trading days preceding the effective date [4] Additional Information - Further details regarding the reverse stock split can be found in the definitive proxy statement filed with the SEC on January 14, 2025 [6]